|
|
|
|
|
by Mistletoe
655 days ago
|
|
> The studies - part of the Select trial - tracked more than 17,600 people, aged 45 or older, as they were given either 2.4 mg of semaglutide or a placebo for more than three years. Participants were obese or overweight and had cardiovascular disease but not diabetes. Exciting stuff. What does data look like in people that aren’t obese? |
|